Furthermore, we present evidence that neoadjuvant neratinib reduces the incidence of brain metastases and provides greater survival benefit than late intervention aimed at treating advanced HER2+ve breast cancer with established brain metastases. The gene discussed is ERBB2; the disease is breast cancer.